Author

Premanjali Lahiri

Observed name: Lahiri, Premanjali

Observed institutions: Annexon Biosciences (United States), Stanford Medicine, Instacart (United States), Stanford University

ORCID: 0000-0001-6885-0448

Observed ORCID: 0000-0001-6885-0448

OpenAlex ID: A5042235344

Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease

2021 · Annalisa Lattanzi, Joab Camarena, et al. · Science Translational Medicine · 171

Genome editing of donor-derived T-cells to generate allogenic chimeric antigen receptor-modified T cells: Optimizing αβ T cell-depleted haploidentical hematopoietic stem cell transplantation

2020 · Volker Wiebking, Ciaran M. Lee, et al. · Haematologica · 73

One Year Follow-up on the First Patient Treated with Nula-Cel: An Autologous CRISPR/Cas9 Gene Corrected CD34+ Cell Product to Treat Sickle Cell Disease

2023 · David C Shyr, Robert Lowsky, et al. · Blood · 29

Cedar Trial in Progress: A First in Human, Phase 1/2 Study of the Correction of a Single Nucleotide Mutation in Autologous HSCs (GPH101) to Convert HbS to HbA for Treating Severe SCD

2021 · Julie Kanter, John F. DiPersio, et al. · Blood · 26

Molecular dynamics of genome editing with CRISPR-Cas9 and rAAV6 virus in human HSPCs to treat sickle cell disease

2023 · Liwen Xu, Premanjali Lahiri, et al. · Molecular Therapy — Methods & Clinical Development · 16

Functional screening in human HSPCs identifies optimized protein-based enhancers of Homology Directed Repair

2024 · Juan A. Perez-Bermejo, Oghene Efagene, et al. · Nature Communications · 9

Αβ T-Cell/CD19 B-Cell Depleted Haploidentical Stem Cell Transplantation: A New Platform for Curing Rare and Monogenic Disorders

2020 · Alice Bertaina, Rosa Bacchetta, et al. · Transplantation and Cellular Therapy · 2

Works count: 8

Citation count: 326

H-index: 6

I10-index: 5